Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADP-A2M10
- Development stage
- Unknown
- Lead developer
- Adaptimmune Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ADP-A2M10 was a genetically engineered autologous T-cell therapy developed by Adaptimmune. It utilized the Specific Peptide Enhanced Affinity Receptor (SPEAR) platform to express an affinity-enhanced T-cell receptor (TCR) that specifically recognized the GLYDGMEHL peptide derived from the cancer testis antigen melanoma-associated antigen A10 (MAGE-A10), presented in the context of human leukocyte antigen HLA-A*02:01 or HLA-A*02:06. The therapy was designed to target and eliminate solid tumor cells expressing MAGE-A10. Clinical trials demonstrated acceptable safety with no evidence of off-target toxicity or alloreactivity. Development was discontinued in favor of therapies targeting MAGE-A4 due to overlapping expression between MAGE-A4 and MAGE-A10.
- Other names
- SPEAR T cells targeting MAGE-A10
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on ADP-A2M10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADP-A2M10.